Trials / Completed
CompletedNCT02278055
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 |
Timeline
- Start date
- 2014-10-08
- Primary completion
- 2022-02-02
- Completion
- 2022-02-02
- First posted
- 2014-10-29
- Last updated
- 2023-04-07
- Results posted
- 2023-04-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02278055. Inclusion in this directory is not an endorsement.